Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | GRM7 | Q14831 | 4/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15483948 | 0.98 | MAPT (0.61) | MAPTGRM7MTNR1AMTNR1BHRH3 | |
| SCHEMBL10421952 | 0.87 | MAPT (0.71) | MAPTGRM7MTNR1AMTNR1BHRH3 | |
| SCHEMBL27731471 | 0.81 | MAPT (0.63) | MAPTGRM7MTNR1AMTNR1BHRH3 | |
| SCHEMBL4865313 | 0.81 | MTNR1A (0.79) | MAPTGRM7MTNR1AMTNR1BHRH3 | |
| SCHEMBL6359193 | 0.81 | MTNR1A (0.79) | MAPTGRM7MTNR1AMTNR1BHRH3 | |
| Hydrochloric Acid SCHEMBL11568569 | 0.80 | MAPT (0.61) | MAPTGRM7MTNR1AMTNR1BHRH3 | |
| SCHEMBL10804933 | 0.79 | MAPT (0.69) | MAPTGRM7MTNR1AMTNR1BHRH3 | |
| SCHEMBL4858101 | 0.79 | MAPT (0.69) | MAPTGRM7MTNR1AMTNR1BHRH3 | |
| SCHEMBL1584190 | 0.79 | MAPT (0.54) | MAPTGRM7MTNR1AMTNR1BHRH3 | |
| SCHEMBL22787538 | 0.77 | MAPT (0.58) | MAPTGRM7MTNR1AMTNR1BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019178267-A2 | INDUCTIVE REGENERATION OF THE AIRWAY BY TRANSCRIPTIONAL FACTOR MODULATION OF GLANDULAR MYOEPITHELIAL STEM CELLS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-09-19 | — | — | WO | claimed |
| US-11971402-B2 | Methods and reagents for determination and treatment of organotropic metastasis | CORNELL UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| US-20210010082-A1 | Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases | VASCULAR BIOSCIENCES (US) | 2021-01-14 | — | — | US | disclosed |
| EP-2977468-B1 | METHODS OF NOVEL THERAPEUTIC CANDIDATE IDENTIFICATION THROUGH GENE EXPRESSION ANALYSIS IN PULMONARY ARTERIAL HYPERTENSION | VASCULAR BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190049435-A1 | METHODS AND REAGENTS FOR DETERMINATION AND TREATMENT OF ORGANOTROPIC METASTASIS | UNITED STATES GOVERNMENT | 2019-02-14 | — | — | US | disclosed |
| US-10137188-B2 | Cell lines for virus production and methods of use | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-3372685-A2 | CELL LINES FOR VIRUS PRODUCTION AND METHODS OF USE | University of Georgia Research Foundation, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20180162862-A1 | INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162862-A1 | INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-06-14 | — | — | US | disclosed |
| EP-3303338-A1 | INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES | President and Fellows of Harvard College (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20110091421-A1 | Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases | VASCULAR BIOSCIENCES, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20080287480-A1 | Therapeutic Combination Comprising a Nmda Receptors Blocker and a Narcotic Analgesic Substance | CHIESI FARMACEUTICI S.P.A. (IT) | 2008-11-20 | — | — | US | disclosed |
| EP-1909781-A1 | THERAPEUTIC COMBINATION COMPRISING A NMDA RECEPTORS BLOCKER AND A NARCOTIC ANALGESIC SUBSTANCE | CHIESI FARMACEUTICI S.p.A. (IT) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007017058-A1 | THERAPEUTIC COMBINATION COMPRISING A NMDA RECEPTORS BLOCKER AND A NARCOTIC ANALGESIC SUBSTANCE | CHIESI FARMACEUTICI S.P.A. (IT) | 2007-02-15 | — | — | WO | disclosed |
| EP-1455771-B1 | 2-INDANYLAMINO DERIVATIVES FOR THE THERAPY OF CHRONIC, ACUTE OR INFLAMMATORY PAIN | CHIESI FARMA SPA (IT) | 2006-11-08 | — | — | EP | disclosed |
| EP-1321139-B1 | 2-Indanylamino deratives for the therapy of chronic, acute or inflammatory pain | CHIESI FARMA SPA (IT) | 2006-08-23 | — | — | EP | disclosed |
| US-20050222266-A1 | 2-indanylamino derivatives for the therapy of chronic pain | CHIESI FARMACEUTICI S.P.A. (IT) | 2005-10-06 | — | — | US | disclosed |
| EP-1455771-A2 | 2-INDANYLAMINO DERIVATIVES FOR THE THERAPY OF CHRONIC PAIN | CHIESI FARMACEUTICI S.p.A. (IT) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003053429-A2 | 2-INDANYLAMINO DERIVATIVES FOR THE THERAPY OF CHRONIC PAIN | CHIESI FARMACEUTICI S.P.A. (IT) | 2003-07-03 | — | — | WO | disclosed |
| EP-1321139-A1 | 2-indanylamino derivatives for the therapy of chronic pain | CHIESI FARMACEUTICI S.p.A. (IT) | 2003-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162862-A1 | INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES | SI, UGGT1, ALPI | MAPT 260/4885GRM7 4298/4885MTNR1A 2812/4885 |
| US-20050222266-A1 | 2-indanylamino derivatives for the therapy of chronic pain | OPRD1, AANAT, OPRL1 | MAPT 1852/4885GRM7 3388/4885MTNR1A 1707/4885 |
| US-20080287480-A1 | Therapeutic Combination Comprising a Nmda Receptors Blocker and a Narcotic Analgesic Substance | OPRM1, OPRK1, GRIN2B | MAPT 1228/4885GRM7 48/4885MTNR1A 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.